Skip to main content
. 2018 Oct 16;9(81):35251–35265. doi: 10.18632/oncotarget.25834

Table 3. Chemotherapeutic regimens.

First-line schedules No. of patients
 Folfox or Capox 9
 Folfox or Capox + Bevacizumab 23
 Folfiri or CapIri 1
 Folfiri or CapIri + Bevacizumab 2
 Folfiri or CapIri + anti-EGFR 6
 Irinotecan + anti-EGFR 0
 Fluoropyrimidines monotherapy 0
 Fluoropyrimidines + Bevacizumab 2
 Anti-EGFR monotherapy 0
 Fluoropyrimidines + Mytomicin-C 0
Second-line schedules
 Folfox or Capox 7
 Folfox or Capox + Bevacizumab 0
 Folfiri or CapIri 8
 Folfiri or CapIri + Bevacizumab 2
 Folfiri or CapIri + anti-EGFR 15
 Irinotecan + anti-EGFR 4
 Fluoropyrimidines monotherapy 3
 Fluoropyrimidines + Bevacizumab 0
 Anti-EGFR monotherapy 1
 Fluoropyrimidines + Mytomicin-C 0
Third line schedules
 Folfox or Capox 1
 Folfox or Capox + Bevacizumab 0
 Folfiri or CapIri 3
 Folfiri or CapIri + Bevacizumab 0
 Folfiri or CapIri + anti-EGFR 0
 Irinotecan + anti-EGFR 3
 Fluoropyrimidines monotherapy 4
 Fluoropyrimidines + Bevacizumab 0
 Anti-EGFR monotherapy 6
 Fluoropyrimidines + Mytomicin-C 9
Re-challenges at any lines of therapy 21